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The anabolic steroid hormones are of key importance in the integrated control of 
metabolic homeostasis and sexual differentiation. Since their initial discovery in the 
1930s, the androgenic hormones, in particular testosterone and its derivatives have been 
appreciated as the major factors in controlling the development and maintenance of male 
sexual characteristics [1].  
Androgen functions are mediated by binding to the androgen receptor (AR), which is 
found to varying extent in a range of tissues [2]. The importance of androgenic hormones 
in glucose and fatty acid metabolism form the mechanistic basis for many of the gender 
differences in the risk of developing a range of diseases, including cardiovascular and 
malignant diseases [3-6]  
This has fueled a considerable interest in androgenic hormone abundance as a risk factor 
for various human pathological conditions as for example androgen insensitivity 
syndrome, the cluster of metabolic derangements referred to as the metabolic syndrome 
[7] as well as benign prostate hypertrophy and prostate cancer [6, 8-10]. 
Given the central role of the AR in mediating downstream effects of androgenic 
signaling, factors controlling AR abundance and activity play a major role in regulating 
overall androgen activity. A number of studies have addressed the relationship between 
AR composition and function, and mutations in the AR gene have major developmental 
implications [11, 12]. However, there are still a number of fundamental issues pertaining 
to the relationship between the AR structure and downstream functions that remain 
elusive. This work was initiated to further investigate some of the functional 
consequences of two well-recognized polymorphisms within the AR gene; the CAG and 
GGN repeat sequences. 
 
Androgen regulation and production  
Androgens are a group of chemically related sex steroid hormones that stimulate and 
control the development and maintenance of male characteristics and are regulated by the 
the hypothalamic-pituitary-testicular hormone (HPT) axis, Figure 1. Androgens also 
affect functions in non-reproductive tissue, such as bone, skeletal muscle and hair growth 
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in both male and females. The gonadotropins, luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) are produced and secreted by the gonadotropic cells of the 
anterior pituitary as a result of the pulsatile secretion of gonadotropin-releasing hormone 
(GnRH) in the hypothalamus [13]. LH interacts with receptors on the testicular Leydig 
cell membrane, and regulates the production and secretion of testosterone, while FSH 
regulates the spermatogenesis [14]. The gonadotropin secretion is controlled by negative 
feedback between the gonads, pituitary and hypothalamus. Testosterone acts on the 
hypothalamus by reducing the hypothalamic pulse generator and inhibits the secretion of 
LH [15], while the main feedback control of FSH secretion is through Inhibin B from the 
Sertoli cells [16]. Testosterone also appears to inhibit the secretion of GnRH, LH and 
FSH by the local conversion of testosterone to estradiol [17]. 
 
 
Figure 1. GnRH is synthesized and released from the hypothalamus. At the pituitary, GNRH 
stimulates the synthesis and secretion of FSH and LH. These processes are controlled by the size 
and frequency of GnRH pulses, as well as by feedback from androgens and estrogens. Low 
frequency GnRH pulses lead to FSH release, whereas high frequency GNRH pulses stimulate LH 
release. (Drawing by Rod Wolstenholme, University of Tromsø 2012) 
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Testicular androgens are synthesized by the Leydig cells in the interstitial tissue [1]. The 
immediate precursor of the gonadal steroids, as well as of the adrenal steroids, is 
cholesterol. The conversion of cholesterol to testosterone requires the action of five 
enzymes: 3β-hydroxysteroid dehydrogenase (3β-HSD), ∆5,4-isomerase, 17α-hydroxylase, 
C17, 20 lyase, and 17β-hydroxysteroid dehydrogenase (17β–HSD) [18], Figure 2. The rate 
limiting step, as in the adrenals, is cholesterol side chain cleavage. The conversion of 
cholesterol to pregnenolone is identical in the adrenals, in the ovaries and in the testes. In 
the latter 2 tissues, however, the reaction is promoted by LH rather than by 
adrenocorticotropic hormone (ACTH). Testosterone is metabolized to 5α-
dihydrotestosterone (DHT) by 5α-reductase as well as to estradiol by the enzyme 











                                                                                                                           
Figure 2. Steroid hormone synthesis in the testis. 17β-HSD, 17β-Hydroxysteroid dehydrogenase; 
3β-HSD, 3β–hydroxysteroid dehydrogenase; DHT, 5α-dihydrotestosterone. 
 
 
DHT is the most potent of the male steroid hormones, and is thought to be approximately 
30 times more potent then testosterone [21]. Testosterone is present in the circulation as 
free testosterone (2-3%) or bound to albumin (~50%) and to sex hormone binding 
globulin (SHBG) (~44%). Free testosterone was long believed to be the main fraction of 
testosterone available to the target organs and tissue and responsible for the biological 
activity [22-24]. The binding between testosterone and albumin, however, is easily 
reversed and together these two fractions are referred to as active testosterone nowadays, 
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or bio-available testosterone [24, 25]. In target tissues, testosterone dissociates from 
carrier proteins and enters the cell via passive diffusion [1]. When bound to the intra 
cellular AR in the cytoplasm, removal of inhibitory proteins and activation of the receptor 
to its DNA binding state takes place. The hormone-receptor complex is transported to the 
nucleus where it undergoes dimerisation and binding to hormone response elements of 
target genes. Transcription activation takes place, resulting in a cellular response, Figure 




Figure 3. The androgen receptor is maintained in an inactive complex in the cell cytoplasm 
bound to heat shock proteins, HSp40, HSP70 and HSP90. Upon ligand binding, conformational 
changes take place and the receptor is phosphorylated. Importin α binds to the nuclear 
localisation signal in the hinge region and mediates transport into the nucleus where it dimerises 




The androgen receptor 
The human AR belongs to the nuclear receptor family of ligand-activated transcription 
factors [27]. Its regulation of transcription is crucial for androgenic effects in individuals 
of both genders, and is important in all phases of human life; differentiation of the sexual 
organs during the embryogenesis and pubertal development with secondary sex 
characteristics that typify the adult man i. e. growth of facial and pubic hair, deepening of 
the voice, development of skeletal muscle mass and bone density as well as sperm 
production [2, 28, 29]. The AR has been detected in a vast array of genital and non-
genital tissues, and can be found not only in the classical androgen-dependent organs, 
such as muscles, prostate, seminal vesicles, epididymis and testes, but also in almost 
every tissue, e.g., hypothalamus, pituitary, kidney, spleen, heart and salivary glands [2, 
30-33]. The classical target cells for DHT are the prostate, seminal vesicles, external 
genitalia, hair follicles, and genital skin [1, 34]. Targets for testosterone include the 
embryonic Wolffian structures, spermatogonia, muscles, bone, kidney, and brain, to 
mention a few [1, 2, 34, 35].  
 
The AR is located on the X-chromosome at Xq11.2–q12 [36, 37], spanning more than 90 
kilobases in length and containing eight exons. The molecular weight is approximately 
110 kDa [33, 38]. Like all other steroid receptors, the AR encodes a protein with three 
major functional domains: the DNA-binding domain, the C-terminal ligand-binding 
domain [37], and the NH2-terminal transactivating domain [39, 40], Figure 4. 
 
The transactivating domain 
The transactivating domain, which is an important determinant of the AR’s capacity to 
influence target genes [33, 41], contains two polymorphic repeats; a stretch of a variable 
number of the amino acid glutamine- as well as a glycinetract encoded by (CAG)nCAA 
and (GGT)3(GGG)(GGT)2(GGC)n, respectively [42]. These sequences are commonly 





Figure 4. Human androgen receptor (AR) gene; structural organization and protein. The AR 
gene was mapped to the long arm on chromosome X. The hAR protein is encoded by 8 exons 
(numbered within boxes), separated by introns. The AR protein consists of several distinct 
functional domains: exon 1 encodes the amino terminal domain involved in transcription 
regulation; exons 2 and 3 encode the DNA-binding domain; the 5´end of exon 4 encodes the 
hinge region including the nuclear targeting signal; the 3´portion of exon 4 and exons 5-8 encode 
the steroid-binding domain. The diagram of the protein structure illustrates the main 
functional domains: the  transcription-regulation domain the trans-activating domain, 




The CAG repeat sequence spans from approximately 10 to 30 repeats, with an average 
length of 22 repeats in Caucasians [43]. Ethnical differences in the CAG repeat length are 
well known [44], with on average shorter repeats in African populations, longer repeats 
in Asians, and intermediate lengths in Caucasians. Abnormal expansion of the CAG 
repeat length (>40CAG) leads to the neuromuscular disease Spinal and bulbar muscular 
atrophy (SBMA) also known as Kennedy’s disease, which is accompanied by signs of 
hypoandrogenism such as
 
gynecomastia, infertility and high plasma concentrations of
 
LH, 
FSH and estradiol [45]. The severity of the neurological features
 
of the disease have been 
inversely correlated to
 
the extension of the CAG repeats [46]. These findings, together 
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with a few in vitro studies [47-49], have supported the hypothesis of an inverse 
correlation between transcriptional activity and the CAG repeat length. The in vitro 
studies showed a significant difference in transactivation between ARs containing the 
shortest and the longest repeat, respectively, with a decreased activity for the longest 
repeat compared with the shortest. Notably, in most previous studies, extreme CAG 
lengths were used. In those with CAG numbers within normal range, the longest repeat 
displayed decreased activity compared to the shortest, but neither the shorter nor the 
longer repeat differed in capability to activate the reporter gene compared to the 
intermediate one [47, 49]. 
 
Regarding the GGN segment little is known so far both with respect to normal 
physiological function and possible pathophysiological conditions. In general, the GGN 
repeats span from 10 to 27, with 23 GGN as the most common variant, carried by 
approximately 50% of Caucasian populations, closely followed by 24 GGN, which 30% 
are carriers of [50]. The importance of the GGN stretch for transcriptional function of the 
AR was first  shown through deletion of the entire repeat, which resulted in 30% 
reduction of the AR activity [51]. More recent in vitro data have indicated that the 23 
GGN allele in combination with 22 CAG gives a higher AR activity compared to longer 
and shorter GGN alleles, respectively [52]. There are no strong associations with any 
diseases reported, although short GGN repeats have been reported to correlate with 
decreased semen volume [43], indicative of lower androgen activity. In middle-aged and 
old men, GGN numbers different from 23 combined with CAG numbers of 23 or less was 
reported to be associated with a higher waist-to-hip ratio [53]. As with the CAG repeat, 
the GGN repeat also varies between populations. Whereas the GGN tract is normally 
distributed in African populations, this is not the case for Caucasians, who have either 23 
or 24 repeats [44]. 
 
The DNA-binding domain 
The central region of the AR, encoded by exon 2 and 3, contains the DNA-binding 
domain (DBD), which is the most highly conserved region among members of the steroid 
hormone receptor family, the AR DNA binding motif having approximately 80% amino 
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acid identity with those of the mineralocorticoid receptor, the progesterone receptor, and 
the glucocorticoid receptor (GR) [30].   
The DBD contains 9 conserved cysteine residues, of which 8 are involved in the 
formation of 2 zinc clusters, arranged as a pair of loop structures folded to form a single 
structural unit made up of two zinc-binding motifs [33, 41, 54, 55]. Four cysteine 
residues, present in all steroid receptors, coordinately bind a zinc atom in a tetrahedral 
array in each of the two motifs, thus commonly referred to as zinc fingers. The first zinc 
finger is encoded by exon 2 and the second zinc finger by exon 3. By analogy with other 
steroid receptors, the DNA binding domain determines the specificity of AR interaction 
with DNA [41]. The ability to discriminate between response elements resides in 3 amino 
acids at the base of the first zinc finger (glycine577, serine578 and valine581), located in 
the so-called proximal box (P-box). These three amino acids interact with transcriptional 
enhancer nucleotide sequences referred to as hormone response elements, present in or 
near target genes [56-58]. The second zinkfinger stabilizes DNA and AR interaction by 
contact with the DNA phosphate backbone. In this part of the AR, a five amino acid 
residue long distal box (D-box) was identified. The D-box is important as it specifies the 
half-site spacing requisite at the hormone response element and provides a site for homo-
dimerisation of ARs [58, 59]. 
 
The hinge region 
The DNA binding domain and the ligand binding domain are coupled by a region of low 
sequence homology among the members of the steroid hormone receptor-family, known 
as the hinge (approximately amino acids 623-671) [56]. This region is encoded by the 
5´portion of exon 4 and contains the major part of the AR nuclear localization signal, 
which consists of two basic amino acid residues, a spacer region of ten amino acids and a 
basic cluster where three of the next five residues must be basic [56]. This bipartite motif 
is conserved among steroid receptors, and for GR and AR, this signal (arg, lys, leu, lys, 
lys at positions 629-633) is necessary and sufficient for hormone dependent nuclear 




The ligand binding domain 
The carboxy-terminal third of the AR, encoded by encoded by the 3´end of exon 4 and 
exons 5-8 comprises the hormone binding domain [30]. A principal function of the AR 
steroid binding domain is the specific, high affinity binding of androgens, but apart from 
binding of hormones, this part of the AR also is involved in dimerisation and in 
transcription activation [41]. Steroid hormone receptors are bound by a complex of 
inhibitory proteins, heat-shock proteins, which are critical for proper folding of the 
receptors, Figure 3. Upon hormone binding, removal of heat-shock proteins, such as 
hsp90, may unmask functional domains and initiate conformational changes necessary 
for nuclear import of the receptor-hormone complex, dimerisation, and DNA binding [33, 
41, 60]. 
 
Androgen related pathological conditions in males 
The androgen insensitivity syndrome. 
Androgen insensitivity syndrome (AIS) is a rare disorder of male sexual differentiation 
caused by an absent or dysfunctional AR [61] It is an X-linked recessive disorder, only 
affecting individuals having a 46,XY karyotype. The phenotype is encompassing a wide 
array of genital ambiguities, which may range from completely female to fertile male 
without complains of undermasculinization [62]. Generally, normal but immature testes 
are present and as differentiation of the embryonic Wolffian ducts occur in response to 
androgens, Wolffian ducts are absent in individuals with AIS. Müllerian ducts are usually 
absent, as the Anti-Müllerian hormone action in the fetus is normal. The syndrome is 
classified into three forms: complete, partial and mild AIS (CAIS, PAIS and MAIS) 
according to the severity [30, 55].  
 
Spinal and bulbar muscular atrophy 
X-linked spinal bulbar muscular atrophy (SBMA) or Kennedy´s disease, is a disorder of 
the motor neurons characterized by the adult onset (usually 30-50 years of age) and the 
slow progression of proximal muscle weakness and atrophy associated with tremor, 
muscle cramps, and weakness, mainly of the tongue, facial muscles, and proximal limb 
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girdle muscles [12, 63-65]. Moreover, affected males frequently present with 
gynecomastia, reduced or absent fertility with oligozoospermia or azoospermia, and high 
plasma levels of LH, FSH and estradiol [64-66]. Such clinical and biological profiles are 
compatible with an AR defect, as observed in PAIS. Affected individuals have normal 
fetal masculinization as evidenced by normal male external genitalia and are often fertile 
in early adulthood [66]. The characteristics of mild androgen insensitivity appearing later 
in life may be related to reduced AR expression and a lower testosterone level observed 
in elderly men [67, 68]. Notably, signs of androgen resistance are often the earliest 
manifestation of Kennedy´s disease, preceding the neurological changes [66]. In 
heterozygous women mild symptoms can be observed, indicating that female carriers are 
protected by chromosome X-inactivation and/or by a lower androgen level [66, 69, 70] . 
La Spada et al. demonstrated that the molecular cause of Kennedy´s disease was an 
abnormal expansion of the CAG stretch in the amino terminal domain of the AR [45]. In 
all 35 patients studied, the number of glutamine residues was expanded to 40-52 repeats 
and no expansion was present in the AR genes of 263 controls. The same study 
demonstrated a correlation between the size of the expanded segment and the severity of 
the disease, but this correlation only seemed to apply to the neurological features of the 
disease and not to the features of androgen insensitivity. Important is, that although the 
morbid gene and the causative mutation leading to Kennedy´s disease is known, the 
pathogenesis is still unknown [71, 72]. Although patients with Kennedy’s disease 
frequently present signs of PAIS, SBMA does not occur in subjects with AIS. This is 
surprising, because androgens are known to play a role in growth, differentiation and 
regeneration of motor neurons. A possible explanation of these conflicting data is, that 
the expansion of the polyglutamine region of the AR would result in a gain of a function 
due to misfolded protein that is selectively toxic for motor neurons, and in a loss of 
normal protein function required for full androgen response [65]. 
 
Male infertility 
Approximately 10-15% of all couples have difficulties of conceiving, making infertility 
one of the most common disorders in the Western world [73]. In 30-50% of the cases, the 
cause is male related, mainly linked to azoospermia and oligospermia [74]. In a small 
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proportion of the infertile men, the explanation is to be found within genetic and other 
molecular abnormalities [74]. Chromosomal abnormalities like Klinefelter’s syndrome 
(47,XXY) and mixed gonadal dysgenesis syndrome may in a few cases be the cause of the 
problem. Mutations in the AR are also sometimes, although not frequently, the cause of 
male infertility [75].  
In some studies also the CAG repeat length was associated with infertility. Tut et al., 
Mifsud et al. and Harkonen et al. reported association between long CAG stretches, 
although within normal length, and male infertility [49, 76, 77]. However, others have not 
been able to find such associations [78-80]. In a meta-analysis from 2007, infertile men 
were shown to have 0.19 repeat longer CAG stretches than fertile men [80].  
 
Prostate cancer 
In Europe, prostate cancer is the most common solid neoplasm in men, with an incidence 
rate of 214 cases per 1000 men, outnumbering colon and lung cancer 
(http://www.uroweb.org) [81]. The true incidence is however difficult to estimate since 
the malignancy is frequently subclinical, detected only via prostate specific antigen 
(PSA) testing. Before PSA-based testing was introduced, mortality from prostate cancer 
was steadily increasing, most likely caused by increasing longevity [82, 83]. However, in 
the USA, age-standardized prostate cancer specific mortality rates have during the last 
years decreased to a level lower than before the era of PSA screening [83]. This is also 
noted in Norway, Sweden and Finland, although rates remain higher than before the PSA 
test became widespread. On the other hand, in some countries, such as Denmark, 
mortality from prostate cancer has continued to increase. 
There are significant ethnic variations in incidence throughout the world, where African 
Americans have the highest incidence rates and Asians the lowest rates [84]. Even within 
countries, there are clear differences in prostate cancer incidence and mortality. In e.g. 
the USA, the risk-adjusted incidence rate in the 60-69 age group is estimated to be >700 
per 100 000 whites and >1200 per 100 000 for blacks [85]. The mortality is also 
substantially higher in African- than Caucasian Americans [86]. However, although 
prostate cancer incidence is also higher for UK blacks than whites, there is no evidence 
that their disease-specific mortality is higher.  
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Because of the pivotal role of androgens and the AR in development of the normal 
prostate and in the pathogenesis of prostate cancer, androgen ablation is a cornerstone in 
the treatment of this disease and numerous investigations regarding AR mutations and re-
arrangements as well as the CAG and GGN polymorphisms have been performed. The 
results show, that germline mutations in the AR gene are rare, only two documented to 
date (http://androgendb.mcgill.ca). With respect to the polymorphic CAG and GGN 
stretches, the results are conflicting, partly because of populations of mixed ethnicities, 
low numbers of participants and determination methods of repeat lengths. Some authors 
report positive associations between shorter CAG repeat length and higher risk for 
prostate cancer [87]. On the contrary, Bratt et al. and Freedman et al. found no 
association between CAG repeat length and prostate cancer [88, 89]. The largest study to 
date on prostate cancer risk and CAG repeat length has been carried out by Lindström et 
al. and included more than 6000 cases and controls [90]. No association between CAG 
length and prostate cancer was reported, but a relation between CAG length and 
circulating levels of testosterone and estradiol was observed. Regarding GGN, several 
studies indicate that men with short GGN repeats have a higher risk of developing 
prostate cancer [91-93].  
 
Testicular cancer 
Testicular cancer accounts for about 1 percent of all cancers in men from Western 
countries [94]. Despite its overall low incidence, it is the most common solid malignancy 
in men between the ages of 15 and 35 years. As in prostate cancer, there are large 
ethnical differences in both incidence rates and mortality rates, with Caucasians having a 
significantly higher risk of developing testicular cancer compared with black African and 
African American populations [95]. Cross-border comparisons of the Organisation for 
Economic Co-operation and Development countries, showed that the highest testicular 
cancer mortality rates can be found in Denmark, Norway and New Zeeland, and the 
lowest in Korea and Japan [96]. There are few risk factors known for testis cancer. 
Although cryptorchidism, infertility and testicular dysgenesis have been proposed as 
contributing factors, the causes remain largely unknown [97, 98]. A genetic basis, with 
main focus on the AR gene and the polymorphic CAG and GGN repeats, has been studied 
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as a possible cause of testicular cancer. However, also regarding this condition the results 
are conflicting [99, 100]. 
 
Aging men 
It is generally accepted that testosterone concentration falls with increasing age [101]. 
Multi-factorial mechanisms have been proposed for this age-related decline in the 
circulating levels of testosterone. Wu et al. reported an increase in serum LH with 
increasing age, suggesting testicular failure as an important factor in this process [102]. 
This idea is also supported by the age-related decrease of the Leydig cells mass [103]. 
Various other changes in the signaling of the HPT axis are also seen as possible 
contributors to the fall in testosterone, including disruption of the pulsatile GnRH 
secretion due to aging, leading to a diminished secretion of LH from the pituitary [104]. 
Impaired testicular function may also be related to reduced blood supply to the testes with 
rising age [103]. These explanations are not mutually exclusive and a wide array of other 
factors such as lifestyle factors and especially obesity has been shown to contribute to the 
variations of endogenous testosterone levels [101, 105].  
Significant association between androgen receptor CAG repeat length and the level of 
free testosterone has been described in men in various age groups [106-109], although not           
in all studies [110]. 
The clinical importance regarding the declining testosterone level among elderly men is 
widely debated, [102, 111, 112], and there is no widespread consensus as to what types 
and degree of symptoms that would favor a diagnosis of acquired androgen deficiency in 
aging men [113]. The 2006 clinical practice guidelines by The Endocrine Society; 
“Testosterone therapy in adult men with androgen deficiency syndromes” suggest that 
the so-called late-onset hypogonadism should be regarded as a clinical and biochemical 
state with rising age, characterized by particular symptoms such as loss of libido and 
erectile dysfunction, together with a low level of serum testosterone [114]. The authors 
advise not to treat androgen deficiency in general, but do not advise against the treatment 
of older men with low testosterone and clear symptoms of hypogonadism [114]. The 
guidelines and the evidential basis for the diagnosis and treatment of low testosterone in 
elderly men have, however, been debated and a more clear differentiation between age-
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related hypotestosteronemia and late-onset hypogonadism is warranted [102, 111, 112]. 
The clinical practice guidelines was recently updated [115], favoring a more restrictive 
approach to less clearly defined hypoandrogenic states. However, the guidelines are still 
short of aspects concerning possible side effects of androgen treatment and the clinical 
efficacy remains unclear [116, 117]. 
 
Androgens in metabolic diseases 
Central obesity, glucose intolerance and high blood pressure are increasingly prevalent 
throughout the industrialized world, and of major concern as public health issues due to 
their contribution to the accelerated development of cardiovascular disease (CVD) [118]. 
These risk factors for both type-2 diabetes and CVD tend to occur together, and define 
the metabolic syndrome [119, 120]. Guidelines from the 2001 National Cholesterol 
Education Program-Adult Treatment Panel III (NCEP) [7] defines metabolic syndrome as 
a clustering of metabolic derangements, including patients with three or more of the 
following components: 
• Abdominal obesity (waist circumference >102 cm)  
• Triglycerides >150 mg⁄ dL (>1.7 mmol⁄L)  
• High-density lipoprotein cholesterol (HDL)  <40 mg ⁄ dL (<1.04 mmol⁄ L)  
• Fasting glucose > 110 mg⁄ dL (>6.1 mmol ⁄ L)  
• Blood pressure >130 ⁄ 85 mmHg. 
 
 
The prevalence of the metabolic syndrome is rapidly increasing, affecting approximately 
30-34% of adults aged 40-75 years in the UK and 35% of all citizens of the United States 
[121, 122]. The large prevalence of the metabolic syndrome and its association with a 
number of lifestyle-related diseases suggest a complex, multi-factorial pathogenesis. 
Given the central roles played by male sex, body fat distribution and fat- and glucose 
metabolism as risk factors, it is tempting to speculate that androgen signaling might be of 
relevance to the development of the metabolic syndrome. Change in body composition is 
associated with lower testosterone [101]. Obesity and especially redistribution of fat mass 
from peripheral to central intra-abdominal deposits is associated with development of 
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type-2 diabetes and CVD [123]. Central obesity is a key element of the metabolic 
syndrome, and is often regarded as a cause rather than a consequence of metabolic 
dysfunction. Insulin resistance is associated with hyperinsulinemia and hyperglycemia 
and may further cause development of dyslipidemia and hypertension. However, it is still 
unclear whether the decline of testosterone in elderly men is a predictor for development 
of the metabolic syndrome [124], or if the sub-clinical testosterone levels found in men 
with the metabolic syndrome is an indication of overweight and poorer health. For 
instance, Kauka et al. [125] and Niskanen et al. [105] have shown an increase in free 
testosterone levels among obese men with the metabolic syndrome undergoing a rapid 
and significant weight loss.    
 
Independent associations between the AR gene polymorphisms and the components of 
metabolic syndrome have been found, such as shorter CAG repeats and low HDL levels 
[126, 127] suggestive of an unfavorable lipid profile. However, despite this potentially 
higher risk profile for atherosclerosis, Hersberger et al. found no evidence of increased 
risk of coronary heart disease in carriers of short CAG repeat sequences [126].  
Thus, apart from its relevance in SBMA, the importance of the CAG repeat length was at 








Aims of the thesis 
The overall aim of this work was to examine the relationship between AR CAG length 
and androgenic effects, both in vivo and in vitro. Specific aims were: 
 
• To examine whether CAG/GGN repeat lengths have an impact on endogenous 
testosterone and LH levels in elderly men participating in the Tromsø study. 
 
• To investigate to which degree the AR CAG and GGN repeat length 
polymorphisms may be associated with the metabolic syndrome as well as with 
the individual components of the metabolic syndrome in elderly men. 
 
• To examine the AR CAG lengths’ influence, if any, on AR activity by comparing 
three AR genotypes with specified
 
CAG lengths in vitro.  
 
• To investigate whether serum concentration of PSA and PSA expression in the 

























All participants were provided with a written informed consent agreement prior to the 
examinations. The studies were approved by the Tromsø Regional Research Ethics 
Committee and the ethical review board of Lund University, respectively. 
 
Study populations 
Elderly men (Paper I, II and IV) 
The Tromsø Study is an ongoing populations based health survey of the inhabitants from 
the municipally of Tromsø, mainly focusing on lifestyle related diseases. The study was 
initiated in 1974 as a response to the high CVD mortality in Norway (Tromsø 1). Since 
then, the study has been repeated five times, in 1979-80 (Tromsø 2), in 1986-87 (Tromsø 
3), in 1994-95 (Tromsø 4), in 2001-02 (Tromsø 5) and in 2007-08 (Tromsø 6) [128].  
In 2005, all men aged 60-80 years who participated in the fifth survey and had a serum 
total testosterone level ≤11 nmol/L (no. 335) were invited to participate in the clinical 
study, “Older men and testosterone”. For each subject, a randomly assigned age-matched 
control with normal levels of testosterone was also invited. The invitation letter informed 
about the purpose of the study, but did not reveal the subject’s testosterone level. Of the 
157 men who attended this subsequent follow-up examination, 69 still had testosterone 
levels ≤11.0 nmol/L, and were included in the study. 124 men with normal testosterone 
levels in 2001 also attended the subsequent follow-up and 104 individuals who still had 
normal levels of testosterone were included as the control-group.  
As testosterone levels have been shown to decrease with increasing age [101] it was 
unexpected that more then half of the men with low testosterone levels in 2001 were 
found to have normal levels four years later. This may be due to the phenomenon 
regression towards the mean; meaning that variables may vary more at their first 
measurement, but tend to close up to the mean value at a second measurement [129, 130]. 
Another plausible explanation may be related to the diurnal variation of serum 
testosterone. The blood samples from 2001 were drawn at any time point between 0800 
and 1800 h, while preferably all samples should have been drawn in the morning when 
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testosterone levels are at their highest. A recent study by Brambilla et al. reported a 
reduction of 10-25% in serum testosterone from 0800 to 1600h, depending on the 
subjects age [131]. Thus, if testosterone was measured in the afternoon in 2001, the 
participant could have been interpreted to have a low testosterone level, even though a 
sample drawn in the morning in the same individual might have been normal. 
 
Military conscripts (Paper IV) 
Previously, approximately 95% of all 18 year old Swedish men had to undergo a medical 
health examination prior to military service. As only those with serious chronic diseases 
were excluded a priori, this group of conscripts closely reflected the general population 
of young Swedish males. A total of 2255 men born between 1979 and 1982 and living 
within 60 km of the city of Malmö in Southern Sweden were asked to participate in a 
study on reproductive health, and 305 men (13,5%) agreed to enter the study [132]. The 
subjects included in the study were all aged between 18 and 21 years (mean 18.2).  
A blood sample was drawn in the morning for both hormonal measurements and DNA 
extraction. Circulating levels of FSH, LH, SHBG, testosterone, PSA and estradiol (E2) 
were measured in all participants on an automated fluorescence detection system 
(Autodelfia, Wallac Oy; Turku, Finland) at the routine clinical chemistry laboratory, 
Uppsala University Hospital. Intra- and total-assay CV values were below 4 and 7.5% 
respectively. The study protocol also included a semen sample.  
As the AR gene is located on the X chromosome, in order to exclude any impact of ethnic 
variation, genotyping of the CAG and GGN repeats was performed in all men with 
mothers of Swedish origin (n = 223). Of these, serum PSA was available for 187, who 
consequently were included in current study. 
 
Men screened for prostate cancer (Paper IV) 
Prostate biopsy material was obtained from a selection of 134 men selected from a PSA 
screening program at the Urological Clinic, Skåne University Hospital, Malmö, Sweden 
to undergo further diagnostic evaluation based on supra-normal (>4 ng/mL) levels of 
PSA. Measurement of PSA in serum of the men in the screening program was performed 
as in the military conscripts. The men were born between 1910 and 1952, with a median 
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age of 67 years. Eighty-nine patients showed evidence of prostate cancer, whereas 45 had 
histological changes consistent with benign hyperplasia of the prostate [133]. All biopsies 
were evaluated by a pathologist. All stages and grades of prostate cancer were included. 
Follow-up was median 29 months for patients with BPH and 41months for cancer 
patients. Nineteen randomly selected biopsy samples were used for this study. Nine men 
had CAG 14-18, five had CAG 22, and five had CAG 26-28. The biopsies were taken for 
prostate cancer diagnosis purposes before any eventual treatment was started. The 
samples were collected during the period 1997-2002 and had been paraffin embedded. 
Two of these samples only contained benign tissue and two samples only had malignant 
tissue. 
 
Blood sample collection and analyses (Paper I, II and IV) 
Serum samples were consecutively analyzed according to standard protocols at the 
University Hospital of North Norway, except from the EDTA buffered blood samples, 
which were stored at -20°C awaiting further DNA analysis. Serum concentrations of 
estradiol, FSH, LH, PSA and total testosterone was determined utilizing an automated 
electrochemical luminescence immunoassay apparatus (Modular E, Roche Diagnostics 
GmbH, Germany). SHBG, insulin and C-peptide were measured by an automated 
chemoluminescence-based assay (Immulite 2000, Diagnostic Product Group, USA). Free 
(unbound) testosterone was calculated using the obtained values for total testosterone and 
SHBG using a fixed albumin value according to the formula of Vermeulen et al. [134]. 
Glucose, serum cholesterol, low-density lipoprotein (LDL), HDL and triglycerides were 
assayed using an automated clinical chemistry analyzer (Modular P, Roche Diagnostics 
GmbH, Germany). Glycosylated hemoglobin (HbA1c) was measured using a high 
performance liquid chromatography method (Variant II, Bio-Rad Labs, USA). 
 
Genetic analyses (Paper I-IV) 
DNA extraction 
In this study, genomic DNA was prepared from peripheral leukocytes by a rapid 
purification procedure as follows: 50 µl frozen blood was thawed, mixed with 400 µl 
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freshly prepared 0.17 M NH4Cl , inverted and left in room temperature for 20 min. The 
samples were spun for 30 sec and the pellet washed 3 times in cold 0.9% NaCl. Finally 
the pellet was suspended in 200 µl 0.05 M NaOH, boiled for 10 min and neutralized with 
25 µl 1 M Tris-HCl (pH 8.0). Five µl was used for each polymerase chain reaction (PCR). 
  
CAG and GGN nucleotide repeat analysis 
In the present thesis, assays of AR CAG and GGN polymorphisms were performed 
according to the protocols of  Lundin et al. [43]. Briefly, the
 
GGN repeat was amplified 
for 35 cycles in an Eppendorf Mastercycler (Eppendorf, Hamburg, Germany). under the 
following conditions: denaturation at 96°C for 45 s, 45 s annealing at 61°C and 1 min 
extension at 72°C, with an initial denaturation step at 96
 
C for 3 min and a  final 
extension step at 72°C for 5 min. The sequence of the forward primer was 5´-
CGGTTCTGGGTCACCCTCA-3´ and the reverse primer sequence was 5´-
TCACCATGCCGCCAGGGTA-3´.  
  
The CAG repeat was also amplified in a PCR with the forward primer: 5´-
TTAGGGCTGGGAAGGGTCTA-3´ and the reverse: 5´-TGGGGCCTCTACGATGGGCT-
3´. The Samples were amplified using the following program: initial denaturation at 96°C 
for 3 min; 35 cycles of 1 min denaturation at 96°C, annealing at 61°C for 45 s and 
extension at 72°C for 5 min.  
 
PCR products were purified, directly sequenced with the reverse primer from the PCR, 
precipitated, re-suspended and run on an eight-capillary Applied Biosystems (Applied 
Biosystems, Stockholm Sweden) sequencing gear.  
 
Plasmid construction (Paper III) 
In this thesis PCR was used for amplification of the human AR 23 GGN region, which 
was selected to generate an expression plasmid with the combination 16 or 28CAG and 
23GGN. A plasmid expressing an androgen receptor with 22CAG and 23GGN repeats 
was already available in the research laboratory. These genotypes were chosen to 
compare the median CAG length in combination with the most common GGN length in 
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white men (22CAG and 23GGN) to longer and shorter CAG repeats within the normal 
range. 
The DNA template for the PCR was human DNA and the reaction was run under the 
following conditions: 1 min denaturation at 96 ºC followed by a 1 min annealing at 56 ºC 
and 3 min extension at 72 ºC. The sequence of the forward primer was 5´-
CCAGAGTCGCGACTACTACAACTTTCC-3´ and the reverse primer sequence was 5´-
CCAGAACACAGAGTGACTCTGCC-3´. 
The PCR products were digested with Kpn1 and BstE11/Eco911, resulting in a 241 bp 
product, only containing the required GGN stretch.  
Two pCMV4 expression vectors containing full length AR cDNA with the required CAG 
repeat length in combination with an unwanted GGN repeat were digested with the same 
enzymes as the PCR product to remove the GGN repeat present. The opened plasmids, 
lacking the GGN repeat, were then purified. 
The digested and purified PCR product (23GGN) was ligated into the opened pCMV4 
expression vectors, resulting in two vectors with 23GGN in combination with 16 or 28 
CAG repeats. These plasmids were transfected into Escherichia. coli DH5α by 
electroporation, amplified and purified. Finally, correct incorporation of the GGN 
fragment and the CAG sequence was verified by direct sequencing on an  
ABI Prism 3730 genetic analyzer (Applied Biosystems, USA). 
 
AR transactivation assay (Paper III) 
In the current work african green monkey kidney cells (COS-1) were used for transient 
transfection of AR expressing plasmids. COS-1 cells were chosen as they do not express 
an endogenous AR, are easy to transfect, and have been used in similar studies previously 
[47, 49]. They express the SV40 large tumour antigen that enables transcription initiation 
at the SV40 origin site in the pCMV4 expression vector [135]. This results in a high copy 
number of the vector with the AR cDNA in each transfected cell [136]. 
The methods used for transfection of plasmids into mammalian cells are based on various 
ways of promoting DNA uptake. In methods using calcium phosphate, small precipitates 
are formed between the DNA and calcium that then are adsorbed by the cell through a 
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poorly understood mechanism [137]. Electroporation, when cells are given a short 
electric shock, is an efficient method to transfer DNA directly into the cell nucleus [138]. 
In liposome based methods, a complex is formed between the DNA and lipids. The 
complex formed fuses with the cell membrane or is taken up into the cell by endocytosis 
[139]. We used a transfection reagent containing a blend of lipids (Fugene 6, Roche 
Diagnostics) and tried various combinations of plasmid concentrations in order to 
optimise the conditions. 
 
For transfection 150 000 cells were seeded in 12-well plates. The cells were grown for 
24h and subsequently co-transfected with 600 ng pCMV4 plasmid containing the AR 
genotype of interest, 200 ng of the reporter plasmid pGL3hPSALuc2 and either 1 ng of 
pCH110β-gal or 5 ng pRL-SV40 renilla as transfection efficiency controls. The pCMV4 
plasmid has a strong cytomegalovirus promoter that, as mentioned earlier, can be 
replicated in COS-1 cells. The reporter plasmid had a human PSA-promoter in front of 
the luciferase gene. Since renilla, β-gal and various other plasmids often are used as 
transfection efficiency controls, our intention was to investigate if the results could be 
influenced by any common transfection efficiency plasmid.  
Cells were grown and kept in Dulbecco´s modified eagle media containing 10% heat 
inactivated fetal bovine serum supplemented with 2 mM glutamine and 0.02% 
gentamicin. 
 
After transfection, cells were left for 24 h before they were washed and new media with 
10 or 100 nM of DHT or R1881, or media with no hormone was added. Since the COS-1 
cells are known to metabolise testosterone, Methyltrienolone (R1881), which is synthetic 
testosterone that can not be converted into DHT by 5α-reductase, was used to study the 
effect of testosterone. The serum used in the media was stripped from hormones. 
Luciferase and renilla activities were assessed by the Dual Luciferase Reporter assay, 
whereas the combination of β-gal and luciferase was assessed by the Dual Light 
Luciferase assay. Total protein amount in each sample was measured by the method of 
Bradford [140], which is a rapid and sensitive method for the quantitation of microgram 
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quantities of protein utilizing the principle of protein-dye binding. The experiment was 
repeated up to 31 times with DHT and six times with R1881. 
To rule out the possibility that differences in activity depended on varying AR 
transcription amount, mRNA was prepared from transfected cells. The mRNA was then 
reverse transcribed to complementary DNA (cDNA) and quantified by qPCR. 
 
Quantitative real-time PCR analysis (Paper III) 
For the measurement of AR expression in COS-1 cells, qPCR using a fluorescent dye 
was performed. Total RNA was extracted from transfected COS-1 cells using the 
commercially available RNeasy mini kit (Qiagen, Sweden). During the process of RNA 
extraction, the RNA was treated with DNAse to ensure that no residual plasmid DNA 
remained, which could be used as false template in the subsequent qPCR reaction. 
Primers that specifically bind to the polyA tail of mRNA molecules were used in the 
reverse transcriptase reaction to sythetise cDNA with the RevertAid First Strand cDNA 
Synthesis Kit (Fermentas, Sweden), utilizing an oligo-dT primer. 
The AR specific primers in the qPCR reaction were designed to be intron/exon spanning 
to facilitate the discrimination of products from chromosomal DNA and cDNA. Primers 
used for AR detection were, forward 5´-AGCCTATTGCGAG 
AGAGCTG-3´ and reverse 5`-GCTTCACTGGGTGTGGAAAT-3´.  
The chosen endogenous gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
was detected with the forward primer 5´-CGACCACTTTGT 
CAAGCTCA-3´ and reverse primer 5´-AGGGGTCTACATGGCAACTG-3´. The AR 
mRNA was quantified by using the comparative CT method. The method is based on 
normalization of fluorescence values for the gene of interest to the values for the 
endogenous control. Three samples of each genotype were analysed in triplicates and the 
data were compared with the expression of 22CAG treated with 10 nM DHT, which was 
set as a reference value and included in each qPCR run. 
 
Enzyme linked immunosorbent sandwich assay (Paper III and IV)  
Methods for estimating or determining specific protein amount most often are antibody-
based techniques. Western blot is commonly used for detection of proteins in cell lysates. 
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It is a combination of fractionating the proteins in the sample based on molecular weight 
by polyacrylamide gel electrophoresis, in which all separated proteins are transferred to a 
solid membrane and specifically detected by using primary antibodies and secondary 
antibodies conjugated to a detectable reagent. The technique is valuable for detecting 
specific proteins, but is a crude method for determining the specific protein amount. 
Instead, enzyme-linked immunosorbent sandwich assay (ELISA) can be used. The 
sandwich ELISA allows accurate determination of protein amount. It is an antibody-
based method where specific antibodies are used to coat a microtiter plate. The sample is 
added, the protein of interest (antigen) is bound to the antibody and the unbound residual 
material in the sample washed away. The amount of bound protein is determined by 
using a second antibody conjugated to a colorimetric, enzyme linked or 
fluorescent/chemiluminescent antibody, which develops a measurable 
colour/fluorescence when substrate is added. To increase the sensitivity of the assay, an 
unconjugated secondary antibody can be used before a third conjugated antibody is 
added. Standard samples, with known antigen concentration, can be included in the 
reaction to give a standard curve. This curve can then be used to determine the amount of 
antigen in each sample [141, 142]. 
In this work a sandwich ELISA was the chosen method to rule out if differences in 
measured luciferase amount were depending on varying AR protein amount. Since no 
purified AR protein that could be set as reference is available on the market, the exact 
amount of AR could not be detected. We therefore used relative amounts with 22CAG as 
reference. The appropriate amount of total protein to be used was decided by running a 
dilution curve on one sample before the analysis of all samples. The dilution curve 
showed which dilution to use to obtain optical density values within the linear range. 
In all the ELISA reactions, lysates from the prostate cancer cell line LnCaP were 
included as positive controls. Untransfected COS-1 cells were used as negative controls.  
 
Time-resolved fluorescence imaging (TRIF, PaperIV) 
Serum PSA measurement is commonly used to screen for prostate disease and in the 
follow up of patients with prostate cancer. Expression of the PSA gene is regulated by the 
AR. In order to determine if AR expression and activity is varying depending on CAG 
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length, the objective was to measure AR and PSA protein amount directly in human 
prostate tissue from men with known genotype. For this purpose, common 
immunohistochemistry can be used, but the signal obtained is not always linear to protein 
amount and the background is often high [143]. 
Instead, the chosen method for direct quantification was TRFI. This is a method where 
specific antibodies directly or indirectly linked to lanthanides are used in combination 
with image acquisition in an epifluorescence microscope. The lanthanides can be excited 
at specific wavelengths and have a long decay time. The long decay time makes it 
possible to obtain images with low background noise and autofluorescence [143]. In 
comparison to immunohistochemistry, TRFI gives a linear relation between signal 
intensity and the specific protein expression; it also allows an automated and improved 
quantification and evaluation of cellular parameters [143]. 
First the method was verified on AR transfected and paraffin embedded COS-1 cells 
treated with 10 nM DHT. The cells were transfected as mentioned earlier with ARs 
harbouring 16, 22 or 28CAG in combination with 23GGN. After harvesting and fixation 
the cells were paraffin embedded. Sections were then prepared for AR protein 
measurement. The primary antibodies were directed against AR and PSA. They were 
conjugated to Europium (Eu) and Terbium (Tb), respectively, making it possible to 
measure both AR and PSA amount from the same sample. 
For the prostate biopsies, TRIF was performed as described above, followed by 
hematoxylin/eosine staining and standard histological analyses. One sample from each 
patient was analysed once. The primary areas of interest were prostate glands, where AR 
expressed in the nucleus of epithelial cells and PSA found in the stromal cells could be 
detected. The Eu signal was obtained with an emission filter set at 615 nm and for Tb, a 
filter at 545 nm was used. This gave separate images with specific Eu and Tb signals 
from the same area. These images were then analysed, resulting in specific density values 
for each region of interest in every image. The mean intensity of the background was 




Statistical analysis  
All statistical tests were two-tailed with
 
statistical significance defined as p < 0.05. The 
data were
 
analysed using the SPSS statistical package for Windows version
 
15.0 (SPSS 
Inc., Chicago, IL, USA). 
In studies I-II, normal distribution was evaluated with determination of skewness and 
histograms. Total and free testosterone and SHBG were considered to be normally 
distributed. LH was slightly skewed, but because it was not used as a dependent variable 
it was not log-transformed. In study I, men with subnormal and normal testosterone 
levels were compared using t-test. Age-adjusted and BMI-adjusted partial correlations 
were used when analyzing for univariate associations. Analysis of variance was used to 
calculate means of total and free testosterone and SHBG by quartiles of CAG and three 
groups (< 23; 23; > 23) of GGN repeat lengths.  
 
In study II, men with subnormal and normal levels and men with CAG repeat lengths 
≤ 21 and > 21 and three groups of GGN repeat lengths (< 23; 23; > 23) were compared 
using Student's t-test. Pearson correlations were used when analysing for univariate 
associations. Multiple regression analyses were performed to identify independent 
predictors of metabolic syndrome components. ANOVA was used to calculate mean 
adjusted CAG repeat lengths according to components of metabolic syndrome.  
In study III, the activity of the most common genotype 22CAG stimulated with
 
10 nM of 
ligand was set to 100% and the mean activities of other
 
genotypes were expressed relative 
to this. The results are presented
 
as means (ranges). The Friedman test was used for over 
all comparison
 
of AR function between the different CAG lengths investigated
 
(16, 22 
and 28) and the Wilcoxon signed ranks test was used for pair wise comparisons between 
the reference (22CAG) and
 
the other genotypes.  
In order to make the in vivo results comparable to our in vitro findings, serum PSA levels 
in the 22CAG group, corresponding to the median length in Caucasians, were used as 
reference in study IV. The two groups – adolescents and elderly men – were analysed 
separately. The results are presented as means (SD). Univariate regression test was used 
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to test for differences in PSA levels between those having CAG<22 or CAG>22 and the 
reference group. The association between CAG number and PSA was also tested with the 
repeat length as continuous variable in partial correlation analyzes. GGN number and 
testosterone level was included in the analysis as confounder. The tissue samples were 
also grouped according to their CAG length, representing short CAG stretches (CAG<22), 
median length (CAG22) and long stretches (CAG>22). The mean and median value of all 
values from one sample and the 25
th
 percentile and 75
th








Main results  
Paper I. Androgen receptor gene polymorphism and sex hormones in elderly men: the 
Tromsø study. 
 
In this nested case-control study on elderly men, we wanted to examine whether CAG 
and/or GGN repeats were significant modulators of serum concentrations of total and free 
testosterone as well as of LH. CAG and GGN repeat length polymorphism within the AR 
was mapped within a population of elderly men encompassing individuals with normal 
(n=104) or subnormal (n=69) levels of serum testosterone Although there was no 
significant differences in average CAG and/or GGN repeat length between the two 
groups, cross-sectional analyses of the total study population showed positive correlation 
between CAG repeat length and total and free testosterone levels. When adjusting for 
body mass index or waist circumference the associations were no longer significant. We 
found no association between GGN repeat length and sex hormones. 
 
Paper II. Androgen receptor gene polymorphism and the metabolic syndrome in 60-80 
years old Norwegian men. 
 
In this study we wanted to investigate to which degree the AR CAG and GGN repeat 
polymorphisms might be related to the metabolic syndrome. In cross-sectional analyses, 
men with CAG repeat lengths ≤21 had significantly higher fasting glucose, C-peptide and 
glycosylated hemoglobin (HbA1c) levels (all p < 0.05). In multiple regression analyses, 
CAG repeat length was an inverse and independent predictor of glucose after an OGTT 
and of HbA1c levels. We also found that men with more than one component of the 
metabolic syndrome had shorter CAG repeat number (p for trend 0.013) than those with 
only one component. Men with metabolic syndrome (≥ three components of the NCEP) 






Paper III. CAG repeat number is not inversely associated with androgen receptor activity 
in vitro. 
 
Our objective was to test the generally accepted hypothesis of a negative linear 
association between androgen receptor function and the CAG repeat numbers. We studied 
ARs with CAG lengths within normal range (16, 22 and 28) in a reporter-assay with the 
human prostate specific antigen promoter as target. With β-galactosidase as transfection 
control, 22CAG had the highest activity (set to 100%) compared with 16CAG [mean 78% 
(range 41–132), p = 0.005] and 28CAG [68% (26–162), p = 0.006]. In these experiments 
the empty control vector also showed high activity (86%, 10- 166). When adjusting for 
renilla-luciferase, 16CAG behaved similar to 22CAG [104% (56–165), p=0.7] and 
28CAG having lower activity [59% (33–101), p=0.004]. When adjusting for AR protein, 
the 22CAG genotype generated the highest activity; 16CAG and 28CAG displaying 20% 
(10–47, p<0.0001) and 12% (5–21, p<0.0001) thereof. Similar results were obtained with 
adjustment for total protein. By normalizing for AR-content, contrary to various control 
vectors, the highest AR activity was confined to the 22CAG and not 16CAG.  
 
Paper IV. Androgen receptor CAG length dependent amount of prostate specific antigen 
in serum and in tissue.  
 
The release of PSA is regulated by androgens acting via the AR. The AR’s effectiveness 
depends on availability of and on polymorphic CAG repeat in the transactivating part of 
the AR. Recently, a non-linear relation between the AR’s ability to drive a PSA-reporter 
gene and the CAG length was reported, suggesting that the AR containing median CAG-
length was the most effective compared to AR’s with shorter or longer CAG repeats. Our 
objective was to investigate whether this in vitro finding also was reflected in PSA 
concentration in serum as well as in the prostate gland.   
In conscripts carrying CAG22, mean serum PSA concentration was 0.86 ng/mL, whereas 
PSA levels in those with CAG<22 was 0.64 ng/mL (p=0.040) and in men with CAG>22 
0.59 ng/mL (p=0.015). Also in older men, PSA was highest in carriers of CAG22, 5.35 
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ng/mL. Those with shorter repeats had 3.24 ng/mL (p=0.08), whereas carriers of 
CAG>22 had mean serum PSA 2.22 ng/mL (p<0.003).  
In non-malignant prostate tissue samples from men with CAG22, 47% and 22% less AR 
protein, respectively, was present compared to short and long repeats, but despite that 
15% higher PSA amount was found compared to both shorter and longer repeats 
(CAG<22, p=0.36; CAG>22, p=0.81).  
Our study shows a CAG length dependent production and blood level of PSA. These 
































The most important goal of this thesis was to examine the relationship between AR CAG 
number and androgenic effects, both in vivo and in vitro. 
 
Ever since the finding of vanishing spermatogenesis in men with Kennedy’s disease, in 
particular the CAG segment has been extensively studied with respect to disorders of the 
male reproductive system. Some in vitro studies in the late 1990-ties were interpreted as 
supporting this hypothesis, which led to the assumption that the CAG stretch is inversely 
associated with AR function, so that the activity was thought to diminish with increasing 
CAG number. In general, however, in vivo data based on this hypothesis showed no or 
limited impact of CAG number on phenotypic characteristics and has generated numerous 
studies on the risk of infertility [78], prostate cancer [80] and serum testosterone levels 
[144] with conflicting results. 
 
CAG repeat length and androgen status in aging men 
The provision of sufficient levels of androgens in aging men is essential to ensure 
maintenance of male sexual health, demonstrated by the variety of symptoms associated 
with low levels of circulating testosterone. Hypogonadism has also been associated with 
lifestyle-related disorders, including diabetes and CVD, particularly in the constellation 
referred to as the metabolic syndrome, as discussed above.  
Within the field of andrology there has been considerable interest in the possibility of 
treating states of testosterone insufficiency by supplying exogenous androgens. The 
scientific evaluation of such strategies is hampered by a lack of consensus definition of 
testosterone insufficiency, especially in aging men. Additionally, our insight into the 
pathophysiological basis for such age-related testosterone insufficiency remains 
incomplete. Based on the widespread belief that AR activity is directly correlated to CAG 
repeat length, it has been proposed that the age-related decline in testosterone levels 
might be exaggerated in individuals harboring short CAG repeat sequences, as suggested 
by some previous studies [107].  
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Our first objective was to evaluate if polymorphisms in the AR should be taken into 
consideration when clinically evaluating testosterone and LH concentrations in elderly 
men. Our data demonstrate a weak positive correlation between CAG repeat length and 
total and free testosterone levels (Paper I). This is in accordance with the results of a 
larger, recent study on 2878 men aged 40-79 years, recruited from eight different 
European countries, the European Male Aging Study (EMAS). The authors also 
suggested that the increase of circulating testosterone levels in men with longer repeats 
can adequately compensate partly or totally for the lower AR activity to prevent apparent 
deficiency of androgen action [144]. Our cohort of men utilized in Paper I was selected 
from the Tromsø study population based on their testosterone levels, and consisted of 
men with subnormal testosterone (≤11.0 nmol⁄L) and men with normal testosterone levels 
(>11.0 nmol/L). The cutoff value for testosterone to define clinically relevant androgen 
deficiency is not clearly defined [145]. This is of importance not only in comparing data 
from different reports, but also for the interpretation of the clinical significance of the 
data obtained. In addition to evaluating differences between the groups, we also 
examined the whole cohort in cross-sectional analyses. When studying genetic 
polymorphisms, adjusting for external factors may be inappropriate, as environmental 
and lifestyle factors would not be expected to affect the genomic constitution of an 
individual. However, testosterone levels are for example closely related to measures of 
adiposity, and we therefore show data both with and without adjustments. Furthermore, 
growing insight into the issue of epigenetics has led to a less clear-cut distinction between 
intrinsic and external factors when looking at phenotypic consequences of genetic factors. 
Our finding that adjusting for BMI or WC eliminates the association between testosterone 
levels and CAG repeat length points at components of the metabolic syndrome as a 
possible link between AR characteristics and testosterone levels. The mechanistic basis 
for this association remains uncertain, but it is well recognized that adipose tissue 
influences the hormonal state, especially in elderly individuals. 
 
Androgen receptor structure and the metabolic syndrome  
Androgen status appears to influence risk of the metabolic syndrome [146], and it was 
therefore logical to investigate whether GGN- and/or CAG polymorphism could 
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constitute a risk factor for the development of the constellation of metabolic changes and 
risk factor complexes referred to as the metabolic syndrome.  
Our result showed consistently that men with lower CAG repeat lengths were associated 
with an unfavorable metabolic profile. Thus, men with CAG repeat length ≤21 had 
significantly higher fasting glucose, C-peptide and glycosylated hemoglobin (HbA1c) 
levels, and CAG repeat length was inversely and independently associated with glucose 
after an OGTT and of HbA1c levels. We also found that men with more than one 
component of the metabolic syndrome had shorter CAG repeat number than those with 
only one component, and finally men with metabolic syndrome had lower CAG repeat 
number. Our results point in the same direction as those reported by Zitzmann et al. and 
Hersberger et al., who found that shorter CAG repeat length is associated with important 
factor predisposing to the MS [126, 127]. In these two independent case-control studies, 
consisting of  110 healthy Caucasian man with mean age 28, and 544 Caucasian men, age 
spanning from 43-70, HDL-cholesterol levels were found to be positively associated with 
the number of CAG repeats. In contrast, other studies challenge our findings of an inverse 
relationship between CAG and the occurrence of the metabolic syndrome or components 
thereof [144, 147]. In a more resent study Zitzmann et al. [147] demonstrated that a low 
number of CAG repeats would be beneficial with respect to metabolic parameters. The 
report showed a positive independent correlation of the CAG repeat number with body fat 
content, leptin and insulin. Campbell et al. [148] reported a positive association between 
CAG repeat length and waist circumference. The largest study by far, the EMAS study, 
found no relationship between CAG repeat length and anthropometric measures, and the 
CAG/hormone relationships were similar in obese and non-obese men. Nor did they find 
any evidence for a relationship between CAG repeat length and blood pressure, insulin 
sensitivity, cardiovascular disease or blood lipid with the exception an inverse correlation 
with triglycerides. On the other hand, this multicenter report did not investigate the 
possible relationship between the CAG repeat polymorphisms and the metabolic 
syndrome per se [144]. The study population was randomly recruited from eight different 
European countries, rising question of effect of race and ethnicity as a possible reason for 
inconsistency findings compared to our report. Compared with our cohort the EMAS 
study also included younger men (40-79 yr.) and mean age was lower (59.9 yr.) as 
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compared to the participants in our study (69.1 yr.). As the number of men developing 
components of the metabolic syndrome increase with age, it is possible that the lack of 
associations in the EMAS study could be related to the younger cohort. Finally, one study 
reported low CAG repeat numbers to be associated with both beneficial and unfavorable 
metabolic parameters, thus, suggesting that the influence of CAG polymorphism on 
overall metabolic status might be complex and non-uniform [149].  
 
CAG repeat length and androgen receptor activity 
Based on our present in vitro data, it seems apparent that the assumed inverse linear 
correlation between CAG repeat length and AR activity does not hold within the normal 
range of repeat sequence lengths. The assumption of linearity stems largely from 
experiments in which normal sequence lengths were compared to the extreme 
trinucleotide expansions seen in patients with Kennedy´s disease. In the study by 
Chamberlain et al. from 1994, CAG lengths of 25, 35, 49 and 77 were compared when 
using the viral mouse mammary tumor virus (MMTV) long terminal repeat promoter and 
stimulating with a supra physiological concentration of DHT [48]. There was a 
significant difference in transactivation between the shortest and the two longest repeats, 
which both are in the range of patients with Kennedy’s disease, but no significant 
difference in activity between those in the upper normal range (25-35CAG). In the study 
by Tut et al. from 1997, the longest repeat (31CAG) displayed decreased activity 
compared to the shortest (15CAG), but neither differed in capability to activate the 
reporter gene compared to constructs of intermediate sequence length (20CAG) [49].  
Since the former in vitro studies mostly were based on extreme CAG lengths and 
reporter-systems containing viral promoters as well as different control vectors, the 
objective of our third study was to investigate ARs with CAG lengths within normal 
range (16, 22 and 28) in a reporter-assay with the human PSA promoter as target (Paper 
III). We also wished to elucidate whether the interpretation of the results was depending 
on the methods used for adjustment of transfection efficiency and protein content. The 
choice of the COS-1 cell line for our in vitro studies were based primarily on the fact that 
they show no endogenous AR expression, as well as technical considerations from 
preliminary experiments, as further discussed above. 
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The results showed that the average allele length, CAG22, was associated with superior 
transcriptional function of the AR compared to shorter (CAG16) and longer (CAG28) 
variants. The result was parallel to previous findings concerning the other polymorphic 
region in exon 1 - the GGN repeat. Also for this triplet, the most common variant 
(23GGN) was in vitro found to give the most efficient receptor [52]. In support of this 
finding is also the recently published report on reanalysed data on nearly 4000 infertile 
men, in which a higher risk of infertility was observed in men with CAG lengths in the 
lowest and highest regions of the normal range [150].  
 
Repeating the experiments in other cell lines, primary cell lines derived from humans, 
might have provided additional support for our findings, but given the relatively crude 
nature of the readout assay, it seems likely that results from this immortalized cell line 
would be applicable to other cell types. Follow-up studies should also evaluate other 
androgen-responsive promoter elements, which would considerably substantiate the 
findings of the present work.  
In light of the current result on the relationship between CAG repeat length and AR 
activity, it would be interesting to reanalyze preexisting data by a two-way analysis 
looking for a shift of CAG repeat sequence distribution away from the 22CAG length that 
seems to provide optimal AR function.  
The regulation of AR activity is determined by the sum of a number of influences, 
including genetic composition (such as CAG/GGN polymorphism), mRNA transcription 
and half-life as well as rate of protein synthesis and degradation. Our in vitro data draws 
attention to a number of methodological considerations when assaying AR activity. 
Extending these observations to the in vivo setting, it is important to recognize that 
several levels of regulation, including epigenetic factors such as DNA methylation and 
RNA interference could be important in controlling the net AR activity at various stages 
of development, including during aging. These issues have not been addressed in the 
current work, but call for caution when inferring a mechanistic link between trinucleotide 
repeat lengths and various alterations in AR signaling.  
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The question is why both short and long CAG repeats would be of disadvantage? In 
general, the glutamine length variance is influenced by both specific sequence 
characteristics and the specific role of the glutamine tract in the protein structure and 
function, [151]. This is illustrated by the fact that CAG repeats in some genes are 
polymorphic whereas others are not [152], indicating critical reasons for maintaining a 
particular CAG repeat length in some proteins. With respect to the AR, there seems to be 
a length of approximately 10-30 repeats that is endured for proper AR function, and that 
can be balanced by both AR protein amount, as has been shown previously, [153, 154], 
and by the secretion of sex hormones in males. In healthy individuals, any impairment in 
AR functionality can be compensated by activation of the HPT-axis and eventually 
higher androgen levels. 
The AR CAG stretch is in the proteins transactivating domain, which interacts with the 
hormone-binding domain [40]. The fact that mutations in the CAG stretch can disrupt this 
interaction [155, 156] or change the protein structure [157] provides evidence that the 
poly-glutamine tract plays a crucial role in ensuring proper function of the human AR 
protein. The interplay between the transactivating and the hormone-binding domains has 
previously been shown to be significantly reduced by shorter or longer CAG repeats than 
the normal range, generating the hypothesis that these repeats serve as flexible spacers to 
separate regions of biological activity while maintaining the capacity to interact with co-
regulators and the transcription machinery [155]. Such a mechanism could explain how 
both increased and decreased CAG lengths can influence AR function and why so many 
conflicting results regarding its physiological impact have been reported. 
 
CAG repeat length and PSA 
About 15% of male cancers in developed countries are prostate cancer [158]. The clinical 
challenges associated with the use of PSA as a marker for prostate cancer are substantial, 
with a need to improve the process of singling out individuals that will benefit from 
surgical intervention. In many centers, men with PSA serum levels above 3 or 4 ng/mL 
are recommended trans-rectal ultrasound and prostate biopsies. Results from two recent 
randomized trials from Europe and the US, provide strong evidence that PSA-based 
screening for prostate cancer is associated with a high risk of over-diagnosing. [159, 
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160].  In the European trial, PSA screening was associated with decreased prostate cancer 
related mortality but at a great cost; approximately 1,410 men needed to be screened and 
48 additional prostate cancer cases would need to be treated to prevent one cancer-related 
death. Given the high prevalence of subclinical disease and the increasing use of the 
biomarker as a screening test, the need for refinement of the test’s predictive power is 
growing. Given the androgen sensitivity of PSA synthesis, it is tempting to speculate that 
the androgen status of an individual could influence levels of PSA within the tissues and 
in the circulation.  
Our in vitro data suggested that polymorphism in the CAG repeat sequence of the AR 
influenced signaling in a PSA promoter, with an optimum seen in patients with 22CAG 
repeats. By comparing this polymorphism and serum PSA levels in a cohort of males, we 
were able to extend this association to the in vivo situation, demonstrating a 
corresponding peak in mean PSA levels in individuals with 22CAG sequences compared 
to both longer and shorter repeats. A similar pattern was found when looking at PSA 
protein expression in biopsies of patients without evidence of malignant disease. Our data 
is suggestive of a correlation between a 22CAG repeat length and the presence of higher 
than average levels of PSA. These findings are adding further challenges to the 
assumption of an inverse correlation between CAG number and AR activity. 
To our knowledge, the CAG22 variant has not been linked to increased risk of any 
disease of the prostate. Carriers of this genotype, who naturally have higher PSA than 
counterparts with shorter or longer repeats, would according to current practice be at risk 
for unnecessary invasive treatment with potential side effects that are associated with a 
prostate biopsy, including erectile dysfunction and incontinence [161]. On the other hand, 
carriers of very short or very long repeats could be at risk for not being detected in a 
PSA-test until incurable state.  
Although the association between CAG repeat length and PSA is likely to be 
mechanistically related to AR activity, it seems unlikely that CAG genotyping would by 
itself improve the stratification of individuals with supranormal levels of PSA. It is, 
however, possible that adjusting the PSA cutoff levels based on CAG repeat length would 
somewhat increase the predictive value of PSA as a marker of malignant disease. Herein 
lies a possibility of reducing the number of histologically negative biopsies, preventing 
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unnecessary invasive procedures. The evaluation of such possibilities would require a 
larger study population, which should be relatively easily achievable given the prevalence 
of PSA screening procedures and the relative ease and affordability of AR CAG 
sequencing. 
 
Only few other studies have examined the relationship between serum PSA level and AR 
CAG length. Mifsud et al. reported a positive association between short CAG repeat 
lengths and total PSA in subfertile men. Likewise, Giwercman et al. found PSA in 
seminal plasma to be inversely correlated with CAG numbers, based on 274 healthy 
military conscripts. These two reports have been conducted on the earlier accepted 
hypothesis of an inverse correlation between the CAG repeat length and AR activity, 
making it difficult to compare their results to our study. Further, both reports have a 
rather mixed study population, of different ethnicities, making generalizations from the 
results difficult, knowing that the CAG repeat distribution display ethnical differences. 
 
Methodological considerations 
In study I and II, the participants were recruited from the general population. The 
attendance rate in the fifth Tromsø survey was 75.7% in the total male cohort and almost 
90% among men between 60-80 years old. Thus, this cohort definitely comprises men 
from an excellent population-based study. However, the rather low number of men 
participating in the study must be considered a weakness. We were aiming to include all 
men with subnormal testosterone and an age-matched control group, but less than half of 
the invited men attended. In addition, more than half of those who attended did not have 
persistent testosterone levels when re-examined, leaving us with approximately 20% of 
the invited cases (30% of the controls). It is likely that a properly conducted meta-
analysis of available data would attain sufficient statistical power to provide a clearer 
picture of the hitherto largely conflicting findings of our results. In this respect, an 
appreciation of the non-linear relationship between CAG repeat length and AR activity 
would add another dimension to such a study. 
Likewise, the low rate of military conscripts participating in Paper III may reduce the 
generalisability, although the participants were selected from a general population of 
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younger men. The low participation rate was probably due to the request for semen 
samples, very similar to a previous Danish study [162]. However, in the Danish study, 
blood samples were drawn also from men who did not want to leave a semen sample, and 
the hormonal values in these men were not different from those who also left a semen 
sample. We therefore believe that also our cohort reflects the general population in this 
area of Sweden. 
Selection bias can be described as a systematic difference between the two groups which 
are being studied, or a systematic difference between those included and those excluded 
from participation in the study [163]. In our case the focus on sexuality and the request 
for semen sample could possibly have influenced men with a more outgoing attitude to 
participate, while other would have been more reluctant to participate. The association 
between higher testosterone levels and risk behavior is well established [164]. 
Furthermore, in a recent publication, men with shorter CAG repeat lengths had higher 
self-reported dominance and prestige. Although the association between repeat length 
and dominance was mediated by physical strength, the relationship between repeat length 
and prestige was not suggesting that AR polymorphisms may have distinct effects on 
physical and psychological outcomes [165]. Thus, we can not rule out potential selection 
bias.  
Adjusting for confounding variables is important in statistical analyzes. A confounding 
variable is an extraneous variable that correlates (positively or negatively) with both the 
dependent and the independent variable in a statistical model and may therefore influence 
the validity of the result [163]. However, if adjustments should be made when analyzing 
the impact of polymorphisms can be questioned. As mentioned above growing insight 
into the issue of epigenetics has led to a less clear-cut distinction between intrinsic and 
external factors when looking at phenotypic consequences of genetic factors. 
Further, cross-sectional studies are useful for finding associations and creating 
hypotheses, but do not give answers with regard to causal relationships between exposure 
and outcome. 
Study III was a laborious work, including more than 30 experiments, taking almost one 
year to finish. The main reason for doing so many experiments was the fact that the topic 
was controversial and we therefore did not want our results to be questioned due to few 
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experiments or regarded as by chance findings. The strategy was to first optimise the 
conditions, repeat the experiments that previously had been done by others [47, 49] and 
to point out the weak points in previous reports. 
For experimental optimisation, only the expression vector containing CAG22 was used, 
in combinations of 100, 200, 400, or 600 ng expression vector and 600, 400, 200 or 100 
ng reporter vector. The amount of DNA that could be transfected was limited by the 
transfection method (maximum 800 ng) as well as the viability of the cells. Different 
hormonal stimulation lengths were also tested (24, 48 and 72 h), of which 24h gave the 
optimal result in terms of AR activity and cell viability. 
One of the objectives of the study was also to show alternative, biologically more 
meaningful ways of performing the experiments by using a physiological promoter and 
by taking actual AR protein amount into consideration instead of various control vectors. 
However, although the AR is expressed in many of the tissues in the human body, only a 
few target genes have been identified. The kallikrein family of genes is one of these, to 
which PSA belongs, and we had access to the PSA promoter – luc construct. This 
approach has resulted in a positive response in the research field and a novel strategy of 
interpreting in vivo data, as was recently discussed in a review article [166].  
In study IV, the low number of biopsies is a limiting factor and the reason for lack of 
statistical significance with respect to AR activity. The reason for this was that very few 
men were carriers of very short and very long CAG repeats, respectively, in the study 




The present knowledge of the relationship between AR CAG repeat and androgenic 
effects is still lacking in many aspects. With the present studies, an additional piece of the 
puzzle has been added, even tough the exact mechanism by witch different CAG repeat 
lengths can affect the AR function remains to be fully illuminated.  
The main conclusions from the in vivo and in vitro studies are: 
• The CAG repeat was positively associated with total and free testosterone, but not 
with LH. The association was lost after adjusting for BMI or WC.  
 
• The GGN repeat was not associated with circulating androgen levels. 
 
• The CAG and GGN repeats are of minor importance when evaluating androgen 
levels in elderly men. 
 
• The CAG repeat was inversely associated with the number of components of the 
metabolic syndrome in elderly men. 
 
• Elderly men with the metabolic syndrome had shorter CAG repeats lengths.  
 
• The CAG repeat lengths affects the trans-activating capacity of the AR, with the 
average CAG length being associated with optimal AR function compared with 
longer and shorter repeat lengths in vitro.  
 
• The serum levels of androgen-sensitive prostate cancer biomarker PSA was 
higher in men with CAG22 as compared to those with shorter or longer repeat 
lengths, in both adolescent and elderly men. Also in non-malignant prostate 
tissue, PSA was higher in men with average CAG length. The results challenge 
the widespread theory of an inverse correlation between CAG number and AR 
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